Skip to main content

Table 4 Intraoperative adverse events

From: Visual quality assessment of the liver graft by the transplanting surgeon predicts postreperfusion syndrome after liver transplantation: a retrospective cohort study

 

PRS (n = 65)

no PRS (n = 57)

P

Hyperfibrinolysisa [n]

2 (3.1%)

2 (3.5%)

1.00

Asystole [n]

0 (0.0%)

1 (1.8%)

n/ac

Cerebral edemab [n]

0 (0.0%)

1 (1.8%)

n/ac

Transfusions

 RBC [U]

10.7 ± 7.3

9.5 ± 9.0

0.12

 FFP [U]

18.0 ± 9.2

17.2 ± 10.3

0.50

 Platelet concentrate [U]

1.6 ± 1.8

1.1 ± 1.5

0.04

 Fibrinogen [g]

3.0 ± 3.2

1.7 ± 2.6

0.01

 PCC [IU]

1313 ± 1610

579 ± 1133

0.01

  1. PRS postreperfusion syndrome, RBC red blood cell concentrate, FFP fresh frozen plasma, PCC prothrombin complex concentrate
  2. adetected by thrombelastometry; bdetected by mydriasis after reperfusion; ctoo little events to calculate P; intraoperative adverse events after reperfusion in 122 liver transplant recipients apportioned by patients with and without postreperfusion syndrome (PRS)